These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 31708774)

  • 1. Phase I Trial of Pyragrel, a Novel Thromboxane Synthetase Inhibitor, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers.
    Zou C; Zuo X; Huang J; Hua Y; Yang S; Yang X; Guo C; Tan H; Chen J; Chu Z; Pei Q; Yang G
    Front Pharmacol; 2019; 10():1231. PubMed ID: 31708774
    [No Abstract]   [Full Text] [Related]  

  • 2. Simultaneous determination of Pyragrel, a novel anti-thrombotic agent, and its two primary metabolites in plasma by HPLC-MS/MS.
    Yang G; Pei Q; Fu C; Huang J; Chen J; Yang S; Xiang Y; Wang J; Tan H; Liu X
    J Pharm Biomed Anal; 2018 Jul; 156():199-205. PubMed ID: 29727781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic Properties and Tolerability of Cycloserine Following Oral Administration in Healthy Chinese Volunteers: A Randomized, Open-Label, Single- and Multiple-Dose 3-Way Crossover Study.
    Zhou H; Wu G; Hu X; Zhu M; Zhai Y; Liu J; Shentu J; Wu L
    Clin Ther; 2015 Jun; 37(6):1292-300. PubMed ID: 25869627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers.
    Li X; Liu C; Zhu X; Wei H; Zhang H; Chen H; Chen G; Yang D; Sun H; Shen Z; Zhang Y; Li W; Yang J; Liu Y; Lai X; Gong Y; Liu X; Li Y; Zhong D; Niu J; Liu B; Ding Y
    Front Pharmacol; 2018; 9():643. PubMed ID: 29973877
    [No Abstract]   [Full Text] [Related]  

  • 6. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, Pharmacokinetics and Pharmacodynamics of TNHH, a Novel Targeted Neutrophil-Inhibitory Hirulog Hybrid Glycoprotein, in Healthy Volunteers.
    Gou ZP; Song ZH; Chen XG; Hu XC; Wang Y; Fan K; Cai YM; Zheng L
    CNS Drugs; 2019 Jun; 33(6):605-614. PubMed ID: 31093952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers.
    Uematsu T; Kosuge K; Umemura K; Nakano M; Terakawa M; Nakashima M
    J Pharm Pharmacol; 1996 Apr; 48(4):380-5. PubMed ID: 8794987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of DP-b99 in healthy volunteers: first administration to humans.
    Rosenberg G; Angel I; Kozak A
    Br J Clin Pharmacol; 2005 Jul; 60(1):7-16. PubMed ID: 15963088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and tolerability of febuxostat after oral administration in healthy Chinese volunteers: a randomized, open-label, singleand multiple-dose three-way crossover study.
    Zhou H; Zheng Y; Wu G; Hu X; Zhai Y; Iv D; Liu J; Wu L; Shentu J
    Int J Clin Pharmacol Ther; 2016 Feb; 54(2):115-24. PubMed ID: 26636422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase I study to evaluate the safety, tolerability, pharmacokinetics and food-effect of Iguratimod in healthy adult volunteers.
    Xiao F; Zhang F; Zhang LL; Wei W
    Eur J Clin Pharmacol; 2018 Jan; 74(1):69-77. PubMed ID: 29051989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, Safety, and Tolerability of Multiple Doses of the Novel Oxytocin Receptor Antagonist Cligosiban in Development for Premature Ejaculation: Two Randomized Clinical Trials in Healthy Subjects.
    Muirhead GJ; Osterloh IH; Whaley S; van den Berg F
    J Sex Med; 2019 Feb; 16(2):213-222. PubMed ID: 30612858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry.
    Liu MY; Meng SN; Wu HZ; Wang S; Wei MJ
    Clin Ther; 2008 Apr; 30(4):641-53. PubMed ID: 18498913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5alpha-reductase inhibitor, in normal subjects treated with single or multiple doses.
    Fujita T; Matsumoto Y; Kimura T; Yokota S; Sawada M; Majima M; Ohtani Y; Kumagai Y
    Br J Clin Pharmacol; 2002 Sep; 54(3):283-94. PubMed ID: 12236849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety, tolerability and pharmacokinetics of trimebutine 3-thiocarbamoylbenzenesulfonate (GIC-1001) in a randomized phase I integrated design study: single and multiple ascending doses and effect of food in healthy volunteers.
    Paquette JM; Rufiange M; Iovu Niculita M; Massicotte J; Lefebvre M; Colin P; Telmat A; Ranger M
    Clin Ther; 2014 Nov; 36(11):1650-64. PubMed ID: 25224876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral AL01211 in Healthy Chinese Volunteers.
    Dong L; Xiang J; Babcock M; Cheng Y; Wang Y; Shen Y; Li L; Tan L; Garovoy M; Hu W; Zheng J
    Clin Drug Investig; 2024 Jun; 44(6):387-398. PubMed ID: 38698285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers.
    Haass-Koffler CL; Goodyear K; Long VM; Tran HH; Loche A; Cacciaglia R; Swift RM; Leggio L
    Eur J Pharm Sci; 2017 Nov; 109():78-85. PubMed ID: 28778464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease.
    Hey JA; Yu JY; Versavel M; Abushakra S; Kocis P; Power A; Kaplan PL; Amedio J; Tolar M
    Clin Pharmacokinet; 2018 Mar; 57(3):315-333. PubMed ID: 29063518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy Volunteers.
    Kansagra KA; Parmar D; Jani RH; Srinivas NR; Lickliter J; Patel HV; Parikh DP; Heading H; Patel HB; Gupta RJ; Shah CY; Patel MR; Dholakia VN; Sukhadiya R; Jain MR; Parmar KV; Barot K
    Clin Pharmacokinet; 2018 Jan; 57(1):87-102. PubMed ID: 28508936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.